Intraocular Lymphoma Treatment Market

Global Intraocular Lymphoma Treatment Market Snapshot (2023 to 2033)

The global intraocular lymphoma treatment market is slated to reach a valuation of USD 1.2 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a 6.7% CAGR until 2033, being valued at USD 2.3 billion. Intraocular lymphomas are rare malignancies, showing a wide spectrum of clinical manifestations. Therefore, its diagnosis appears to be highly challenging.

Almost all intraocular lymphomas are non-Hodgkin’s lymphomas, and the vast majority are of B-cell origin. Because patients are largely asymptomatic, the disease may go undiagnosed in some cases. However, a majority of them experience a painless reduction in vision or floaters.

Consensus guidelines for treating primary vitreoretinal lymphoma (PVRL)- a type of intraocular lymphoma- have not been firmly established. But local delivery of intravitreal methotrexate or rituximab is reported to have been effective and well-tolerated. Alternatively, patients also undergo bilateral external beam radiotherapy. This is especially for those who are intolerant to intravitreal chemotherapy.

Developments with regard to the diagnosis and treatment of intraocular lymphoma have been significant, given the prevalence of various kinds of ocular cancers across the world:

• The American Cancer Society estimates that as of 2023, there will be around 3,490 new cancers, mainly melanomas, of the eye and orbit. There will likely be 1,900 cases among men, and 1,590 in women
• About 430 deaths occur from cancers of the eye and orbit- 240 men and 190 women
• Worldwide, at least 2.2 billion people suffer from vision impairment or blindness, according to the World Health Organization. Cancers make up a significant portion of the said impairments
• Primary eye cancers may occur at any age, but risks are heightened especially among the geriatrics

Data Points	Key Statistics
Expected Market Value (2023)	USD 1.2 billion
Projected Forecast Value (2033)	USD 2.3 billion
Global Growth Rate (2023 to 2033)	CAGR of 6.7%

2018 To 2022 Intraocular Lymphoma Treatment Market Demand Analysis Vs. Forecast 2023 To 2033

The global Intraocular lymphoma treatment market grew at a CAGR of 5.1% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

The increasing incidence of non-Hodgkin lymphoma globally is one of the major reasons propelling market expansion. Also, the aging population, which is more susceptible to these diseases, is propelling market growth.

The discovery of new immune checkpoint inhibitors, which stop proteins from joining together and strengthen T-cell responses against the cancer cells, is one example of a technical development that is fueling the expansion of the intraocular lymphoma market. As a result, the global Intraocular Lymphoma Treatment Market is expected to forecast a CAGR of 6.7% from 2023 to 2033.

Prominent Growth Drivers Influencing Intraocular Lymphoma Treatment Market

Enhanced biomarkers are triggering the market expansion

Intriguing opportunities are being created for companies in the worldwide intraocular lymphoma treatment market by the use of distinctive and technologically advanced biomarkers in the diagnosis and management of intraocular lymphoma. More sophisticated blood biomarkers are being used, which can increase the accuracy of lymphoma diagnosis by symptom detection. Also, they can assist medical practitioners in identifying the symptoms more quickly than using traditional approaches. In the near future, this is anticipated to have a favorable impact on the market for intraocular lymphoma treatments worldwide.

Genetic biomarkers, physiological biomarkers, radiographic biomarkers, and histological biomarkers are a few of the new improved biomarkers that are progressively being employed for the diagnosis and treatment reasons in the worldwide intraocular lymphoma treatment market. The worldwide market for intraocular lymphoma therapy is anticipated to rise over the next few years as a result of research and development efforts to create novel, technologically enhanced detection technologies for effective biomarkers.

People with weak immunity are susceptible to this disease and needs treatment

Individuals who have compromised immune systems are susceptible to developing primary intraocular lymphoma (PIOL). The risk of acquiring intraocular lymphoma is thought to be increased in older adults and those with weakened immune systems. Additional danger signs consist of:

• Autoimmune diseases such as HIV/AIDS
• Epstein-Barr virus infection
• Anti-inflammatory medications

Cellular alterations in some persons may make them more likely to develop intraocular lymphoma. As a result, it is anticipated that further research and development will be opening up new avenues for the market players during the forecast period.

What Could Possibly Hinder Intraocular Lymphoma Treatment Market Demand?

Higher costs for the treatment is expected to impede the market growth

The market is expected to be hampered by the high cost of treatments. The majority of emerging and underdeveloped nations are affected by this issue since the government sector receives too little funding. For people in many nations, the rising cost of anti-cancer medications is a significant problem. There is intense pressure to reduce expenses and demonstrate value.

Funding for public health care is at danger in many countries due to political unpredictability and ongoing economic pressures. The population health of less developed nations has been impacted by a shortage of affordable medications, which has led to a shorter life expectancy rate. These hurdles are expected to hinder the market expansion from 2023 to 2033.

Region-wise Analysis

What is the outlook of the North American Intraocular Lymphoma Treatment Market?

Rising incidence of eye cancer cases along with lymphomas in the eye will boost the growth

During the forecast period, the North American market for intraocular disease is expected to be the most volatile one. As per Future Market Insights, this region is expected to prolifer with a robust CAGR of 6.9% from 2023 to 2033.

According to the American Cancer Society's projections, there will be an estimated:

• 3,490 new cases of eye and orbital cancer, mostly melanomas (1,900 in men and on the other hand 1,590 in women)
• 430 people per year die from eye and orbital malignancies (240 in men and 190 in women)

Primary intraocular lymphoma can strike at any age, however the likelihood of developing most kinds rises with age. In North America, the incidence of uveal melanomas has remained mostly constant over the past few decades, whereas that of conjunctival melanomas has gone up. Primary intraocular lymphoma is less prevalent than secondary eye malignancies, which are lymphomas that have progressed from another region of the body to the eye.

Adult melanomas often affect the eye and orbit, although this malignancy more frequently develops in other regions of the body. More than 90% of melanomas have a cutaneous origin. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.

What can be expected from the Asia Pacific market for Intraocular Lymphoma Treatment?

Increasing healthcare developments and lower eye melanoma in patients to accelerate the growth

During the forecast period, the Asia Pacific market for Intraocular Lymphoma Treatment is expected to garner a steady CAGR of 6.1%. The Asia Pacific intraocular lymphoma therapy market is anticipated to grow quickly throughout the time of forecasting.

The market in the area is anticipated to be driven by rising healthcare spending, the pharmaceutical industry's rapid growth, and significant unmet demands. The Asia Pacific intraocular lymphoma treatment market is anticipated to grow during the projected period as a result of technological developments in the market for treating ocular lymphoma and a rise in disposal income.

In Asia Pacific's highly populated nations, the elderly population is also increasing, which is a potential driver for intraocular lymphoma. Asians and people of color develop intraocular lymphomas as they age because they have a lower prevalence of eye melanoma, according to the American Academy of Ophthalmology. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.

Category-wise Insights

Which drug segment is expected to gain traction during 2023 to 2033?

The Rituximab segment will gain the dominant market share

Over the course of the forecast period, the Rituximab segment by drug type is anticipated to occupy a significant share of the global Intraocular Lymphoma Treatment Market. In 2023, this category is anticipated to dominate with a 43% revenue share.

When systemic treatment is not an option, intravitreal rituximab may assist establish local control of CD-20 positive secondary intraocular lymphoma. The beneficial therapeutic benefits of rituximab did not appear to be interfered with by a full pars plana vitrectomy in many cases, leading to successful treatment of intraocular lymphoma. Such factors are expected to accelerate the growth prospects for Intraocular Lymphoma Treatment from 2023 to 2033.

Which end-user segment is expected to gain traction during 2023 to 2033?

The specialty clinics segment will demand during the forecast period

Future Market Insights' study indicates that the specialty clinics market would expand throughout the projected period. From 2023 to 2033, it is predicted that this market sector would have a 25% share of the global market.

Patients who have intraocular lymphoma prefer going to an eye clinic over a hospital. These speciality clinics provide patients with a wide variety of medical professionals and treatment alternatives. On the other hand, compared to hospital care, the cost of treatment here is fairly reasonable. As a result, in 2023, this market segment is anticipated to account for over half of the worldwide intraocular lymphoma market.

Start-up Scenario

The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.

• PinoTBio, a South Korean firm, provides focused treatments for cancer and ophthalmology related to the eye. With the company's patented technique, specific therapeutic agents are created by modifying and configuring nucleoside analogues. Treatments for solid tumors, acute myeloid leukemia, and glaucoma are all part of Pinot Bios pipeline.

How Competitive is the Market for Intraocular Lymphoma Treatment?

From major pharmaceutical and healthcare companies to key research institutes, the intraocular lymphoma treatment landscape is interspersed with a significant number of players- offering superior quality research & development capabilities, drugs, and other treatment alternatives. Most players are involved in conducting clinical trials to verify the efficacy of various treatment approaches and drug candidates.

Some of the prominent developments of the key players of the market are:

• In 2021, the clinical-stage biotechnology firm Gossamer Bio, Inc. reported the inclusion of two CNS-penetrant Bruton's tyrosine kinase (BTK) inhibitors to it's own product candidate portfolio. The company is dedicated to finding, acquiring, developing, and commercializing therapies in the pathological conditions of inflammation, immunology, and cancer. The first of those candidates, GB5121, were the subject of first-in-human investigations beginning in the final quarter of 2021, according to Gossamer. For relapsed/refractory primary CNS lymphoma (PCNSL), in which a possibly registrational Phase 1b/2 research was started in the first half of 2022, Gossamer plans to develop GB5121 in the coming years.
• Pembrolizumab is marketed under the trade name Keytruda by Novartis AG. It is used to treat intraocular melanoma as part of cancer immunotherapy. It is gently injected through a vein. Pembrolizumab is a kind of immunotherapy medication. The immune system's capacity to combat cancer cells is strengthened by it. Pembrolizumab targets and blocks the activity of PD-1, a protein that is present on the surface of some immune cells called T-cells. T-cells are stimulated to seek out and kill cancer cells by blocking PD-1.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 6.7% from 2023 to 2033
Market value in 2023	USD 1.2 billion
Market value in 2033	USD 2.3 billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	USD Billion for Value and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Class, Mode of Administration, Distribution Chanel, End User, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Celgene Corporation; Genentech Inc.; Gossamer Bio Inc.; Seagen Inc.; National Cancer Institute; Northwestern University; Astex Pharmaceuticals; Novartis AG; F. Hoffmann-La Roche Ltd.; Pfizer Inc.
Customisation Scope	Available on Request

Key Segments Covered In The Intraocular Lymphoma Treatment Market Report

By Drug Class:

• Methotrexate
• Rituximab
• Cisplatin

By Mode of Administration:

• Injectable
• Oral

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User:

• Hospitals
• Specialty Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Intraocular Lymphoma Treatment Market’s Growth Potential?

The CAGR of the market is 6.7% through 2033.

What is the Current Intraocular Lymphoma Treatment Market Valuation?

In 2023, the market is anticipated to be worth USD 1.2 billion.

What is the Projected Size of The Market by 2033?

By 2033, the market is anticipated to hit USD 2.3 billion.

What is Asia Pacific’s Growth Prospect?

The market in Asia Pacific to attract a persistent CAGR of 6.1%.

What is the Growth Outlook of North America?

The North American market may progress at a 6.9% CAGR from 2023 to 2033.

How is the Historical Performance of the Market?

During 2018 to 2022, the market grew at a CAGR of 5.1%.

Which is the Leading Segment in the Market by Drug?

with a 43% revenue share, the Rituximab sector may rule.